Worcester’s RXi Pharmaceuticals has won a $600,000 grant from the National Institutes of Health for pre-clinical development of RNAi therapeutics.
The Advanced Technology Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases will provide $300,000 per year in 2010 and 2011. The company can also apply for a second phase of funding that could provide up to $1 million per year for three years after the first phase is completed.
RXi’s primary focus is developing treatments for skin and eye disorders, and it also does work in oncology and spinal cord delivery of therapies.
